KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer].

X Y Shao, Q Y Zhang, Z F Niu, M Li, J F Wang, Z Z Chen, R Z Luo, G D Qiao, J G Wang, L Y Qian, R H Yang, Z D Chen, J Wang, Y M Yao, J H Ou, T Sun, Q Cheng, Y S Wang, J Huang, H Y Zhao, W Y Su, Z Ouyang, Y Ding, L L Chen, S M Yang, M S Cui, A M Zang, E X Zhou, P Z Fan, J Zhang, Q Liu, Y E Teng, H Li, J Y Nie, J Yang, X J Wang, Z F Jiang

Zhonghua Zhong Liu Za Zhi 47(4) 340-348

PMID40268551
PMCID-
DOI10.3760/cma.j.cn112152-20240126-00051
发表日期2025-04-23
入排依据:The study is a Phase III randomized trial of a drug intervention in oncology patients with primary results. However, it is not eligible because the primary efficacy endpoint is not a time-to-event outcome (OS, PFS, DFS, etc.). The primary endpoint is a pharmacodynamic measure (cumulative probability of maintaining menopausal hormone suppression level), and other endpoints are hormone changes, PK, and safety. No time-to-event analysis (e.g., Kaplan-Meier, HR for survival) is reported.
摘要

摘要

Background: To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex® in Chinese patients with premenopausal breast cancer. Methods: From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex® every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results: A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex®. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex®. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex® group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion: LY01005 is as effective as Zoladex® in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。